Severe Mental Illness — MCQs
On this page
A 27-year-old man with schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and quetiapine at therapeutic doses for adequate durations. He has poor insight and refuses depot medication. His family reports good compliance with witnessed medication taking. Before starting clozapine, which investigation result would be an absolute contraindication?
A 31-year-old woman with paranoid schizophrenia presents with sudden onset of fever (39.2°C), muscle rigidity, and reduced consciousness. She was started on haloperidol 10mg twice daily 5 days ago. Examination shows lead-pipe rigidity and profuse sweating. Blood tests show: WBC 16.2 × 10⁹/L, CK 8500 U/L, creatinine 165 μmol/L. Which pathophysiological mechanism best explains this clinical syndrome?
A 52-year-old man with bipolar affective disorder has been taking lithium carbonate for 12 years with good effect. Recent annual monitoring shows: eGFR 52 ml/min/1.73m² (previously 78 ml/min/1.73m² two years ago), lithium level 0.7 mmol/L, TSH 6.2 mU/L. He has had no mood episodes for 5 years. What is the most appropriate next step in management?
A 35-year-old woman with schizoaffective disorder has been stable on amisulpride 800mg daily for 3 years. She presents with amenorrhoea for 6 months and galactorrhoea. Blood tests show: prolactin 4500 mU/L (normal <500 mU/L), TSH 2.1 mU/L, negative pregnancy test. MRI pituitary is normal. She refuses to switch antipsychotic. What is the most appropriate management strategy?
A 29-year-old man presents with a 2-month history of believing he is Jesus Christ and that he must save humanity. He has grandiose delusions, pressured speech, reduced sleep (3 hours nightly), and has spent his entire savings. He has no past psychiatric history or substance use. Which additional feature would most strongly suggest a diagnosis of bipolar affective disorder type I rather than schizophrenia?
A 44-year-old woman with chronic paranoid schizophrenia on clozapine 600mg daily attends for routine blood monitoring. She is clinically well with no new symptoms. Her blood results show: WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L, haemoglobin 128 g/L. What is the most appropriate immediate action?
A 38-year-old man with bipolar affective disorder type I has been stable on lithium for 6 years. He presents to A&E with a 48-hour history of vomiting and diarrhoea following gastroenteritis. He appears clinically dehydrated. His lithium level taken 6 hours ago is 1.3 mmol/L. What is the most appropriate immediate management?
A 26-year-old woman with a first episode of psychosis has been treated with aripiprazole 15mg daily for 8 weeks. Her positive symptoms have completely resolved. She asks about duration of treatment. According to current NICE guidelines, what is the minimum recommended duration of antipsychotic treatment following complete remission of a first episode of psychosis?
A 41-year-old man with a 15-year history of bipolar affective disorder presents with tremor, confusion, and ataxia. He takes lithium carbonate 800mg twice daily. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, urea 9.8 mmol/L, creatinine 145 μmol/L, lithium level 2.1 mmol/L. Which medication started in the past week is most likely responsible?
A 32-year-old woman with schizophrenia has been stable on paliperidone palmitate depot injection (150mg monthly) for 18 months. She now wishes to conceive. Her last depot injection was 2 weeks ago. What is the most appropriate management plan?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 51: A 27-year-old man with schizophrenia has persistent auditory hallucinations despite trials of risperidone, olanzapine, and quetiapine at therapeutic doses for adequate durations. He has poor insight and refuses depot medication. His family reports good compliance with witnessed medication taking. Before starting clozapine, which investigation result would be an absolute contraindication?
- A. Prolonged QTc interval of 485 milliseconds on ECG
- B. Neutrophil count of 1.8 × 10⁹/L on baseline blood test (Correct Answer)
- C. History of epileptic seizure 5 years ago, now seizure-free without medication
- D. Mild left ventricular systolic dysfunction with ejection fraction of 48%
- E. BMI of 32 kg/m² with impaired fasting glucose of 6.5 mmol/L
Explanation: ***Neutrophil count of 1.8 × 10⁹/L on baseline blood test*** - A baseline **Absolute Neutrophil Count (ANC)** below 2.0 × 10⁹/L (or 1.5 × 10⁹/L depending on specific local guidelines like the FDA) is an **absolute contraindication** to starting clozapine. - This restriction is vital to mitigate the risk of **life-threatening agranulocytosis**, which occurs in approximately 1-2% of patients treated with clozapine. *Prolonged QTc interval of 485 milliseconds on ECG* - While clozapine can cause **QT prolongation**, a value of 485 ms is considered a **relative contraindication** rather than an absolute one. - Initiation would require specialist **cardiac consultation** and frequent ECG monitoring rather than an immediate disqualification. *History of epileptic seizure 5 years ago, now seizure-free without medication* - Clozapine is known to **lower the seizure threshold** in a dose-dependent manner, but a remote history of seizures is not an absolute barrier. - Treatment can often proceed with **prophylactic anticonvulsants** or cautious dose titration and monitoring. *Mild left ventricular systolic dysfunction with ejection fraction of 48%* - This represents **relative caution**; although clozapine is associated with **myocarditis** and **cardiomyopathy**, mild dysfunction does not strictly prohibit use if the clinical need is high. - Absolute contraindications are reserved for **severe cardiac disease** or clinically unstable heart failure. *BMI of 32 kg/m² with impaired fasting glucose of 6.5 mmol/L* - These are markers of **metabolic syndrome**, a common side effect of second-generation antipsychotics, requiring strictly managed **metabolic monitoring**. - While they increase the risk of **type 2 diabetes**, they do not prevent clozapine use for treatment-resistant schizophrenia.
Question 52: A 31-year-old woman with paranoid schizophrenia presents with sudden onset of fever (39.2°C), muscle rigidity, and reduced consciousness. She was started on haloperidol 10mg twice daily 5 days ago. Examination shows lead-pipe rigidity and profuse sweating. Blood tests show: WBC 16.2 × 10⁹/L, CK 8500 U/L, creatinine 165 μmol/L. Which pathophysiological mechanism best explains this clinical syndrome?
- A. Excessive dopaminergic stimulation in the nigrostriatal pathway
- B. Severe dopamine receptor blockade in the hypothalamus and striatum (Correct Answer)
- C. Serotonin syndrome from excessive serotonergic activity
- D. Cholinergic excess from acetylcholine accumulation
- E. GABA receptor antagonism in the central nervous system
Explanation: ***Severe dopamine receptor blockade in the hypothalamus and striatum***- This patient presents with **Neuroleptic Malignant Syndrome (NMS)**, which is driven by massive **D2 receptor antagonism** following high-potency antipsychotic use (e.g., haloperidol).- Blockade in the **hypothalamus** disrupts thermoregulation leading to high fever, while blockade in the **striatum** causes the characteristic **lead-pipe rigidity** and massive **CK elevation**.*Excessive dopaminergic stimulation in the nigrostriatal pathway*- This mechanism is characteristic of **levodopa** therapy or stimulant use and would typically present with **dyskinesias** or psychosis rather than rigidity.- NMS is specifically caused by a **deficiency or blockade** of dopamine, not an excess of it.*Serotonin syndrome from excessive serotonergic activity*- While it also features fever and altered mental status, it is distinguished by **hyperreflexia** and **clonus** rather than lead-pipe rigidity.- It is associated with **SSRI** or **MAOI** use rather than dopamine-blocking anti-psychotics like haloperidol.*Cholinergic excess from acetylcholine accumulation*- This typically results from **organophosphate poisoning** and presents with symptoms like **bradycardia**, miosis, and diarrhea (DUMBELS).- It does not cause the severe muscular rigidity or the specific pattern of **hyperthermia** seen in NMS.*GABA receptor antagonism in the central nervous system*- GABA antagonism primarily results in **seizures** and CNS excitability due to a lack of inhibitory signaling.- It is not the physiological basis for the autonomic instability and **muscle breakdown** observed in this patient.
Question 53: A 52-year-old man with bipolar affective disorder has been taking lithium carbonate for 12 years with good effect. Recent annual monitoring shows: eGFR 52 ml/min/1.73m² (previously 78 ml/min/1.73m² two years ago), lithium level 0.7 mmol/L, TSH 6.2 mU/L. He has had no mood episodes for 5 years. What is the most appropriate next step in management?
- A. Continue lithium as current level is therapeutic and benefits outweigh risks
- B. Stop lithium immediately and switch to sodium valproate
- C. Reduce lithium dose and recheck levels and renal function in 3 months
- D. Refer to nephrology and consider switching to alternative mood stabilizer (Correct Answer)
- E. Add levothyroxine for hypothyroidism and continue lithium unchanged
Explanation: ***Refer to nephrology and consider switching to alternative mood stabilizer*** - The patient exhibits a **significant decline in eGFR** (from 78 to 52 ml/min/1.73m²), indicating **Chronic Kidney Disease (CKD) stage 3a** likely due to long-term lithium use. - According to **NICE guidelines**, a rapid decline in renal function or an eGFR <60 ml/min requires **specialist nephrology referral** and a multidisciplinary review to transition to alternative mood stabilizers like **valproate or quetiapine**. *Continue lithium as current level is therapeutic and benefits outweigh risks* - Ignoring a decline of **26 ml/min in eGFR** over just two years risks permanent **end-stage renal disease** and lithium toxicity. - While the lithium level is **0.7 mmol/L (therapeutic range)**, the progressive renal impairment suggests the patient is no longer tolerating the drug's systemic effects. *Stop lithium immediately and switch to sodium valproate* - **Abrupt discontinuation** of lithium after 12 years of stability carries a very high risk of **relapse** into mania or depression. - The transition should be gradual and supervised by a psychiatrist, as immediate withdrawal can trigger a **rebound effect**. *Reduce lithium dose and recheck levels and renal function in 3 months* - Dose reduction may lower the serum level, but it does not address the **progressive nature** of lithium-induced **nephropathy**. - Delaying a specialist referral for three months is inappropriate given the **rate of renal decline** already observed. *Add levothyroxine for hypothyroidism and continue lithium unchanged* - While the **TSH of 6.2 mU/L** indicates **subclinical hypothyroidism** (common with lithium), it is a secondary concern compared to the renal failure. - Treating the thyroid alone does not mitigate the **interstitial fibrosis** and tubular damage occurring in the kidneys due to chronic lithium exposure.
Question 54: A 35-year-old woman with schizoaffective disorder has been stable on amisulpride 800mg daily for 3 years. She presents with amenorrhoea for 6 months and galactorrhoea. Blood tests show: prolactin 4500 mU/L (normal <500 mU/L), TSH 2.1 mU/L, negative pregnancy test. MRI pituitary is normal. She refuses to switch antipsychotic. What is the most appropriate management strategy?
- A. Add cabergoline to reduce prolactin levels while continuing amisulpride (Correct Answer)
- B. Add bromocriptine as it does not interact with antipsychotics
- C. Switch to aripiprazole despite patient refusal as hyperprolactinaemia is dangerous
- D. Reduce amisulpride dose to 400mg daily and monitor symptoms
- E. Continue current treatment and provide reassurance as hyperprolactinaemia is benign
Explanation: ***Add cabergoline to reduce prolactin levels while continuing amisulpride***- **Amisulpride** is a potent **D2 antagonist** known for causing significant **hyperprolactinaemia**, and adding a dopamine agonist like **cabergoline** is an effective strategy when a patient refuses to switch antipsychotics.- Research suggests that **cabergoline** can normalize prolactin levels and resolve symptoms like **galactorrhoea** and **amenorrhoea** without necessarily exacerbating psychotic symptoms.*Add bromocriptine as it does not interact with antipsychotics*- While **bromocriptine** is a dopamine agonist, it is generally **less well-tolerated** than cabergoline and has a higher risk of worsening **psychotic symptoms**.- It does interact functionally with antipsychotics by acting on the same **D2 receptors**, potentially neutralizing the antipsychotic effect.*Switch to aripiprazole despite patient refusal as hyperprolactinaemia is dangerous*- Forcing a medication switch against a stable patient's wishes violates **autonomy** and significantly increases the risk of **treatment disengagement** and **relapse**.- Although **aripiprazole** (a partial agonist) effectively lowers prolactin, clinical management must balance physiological risks with the patient's **mental stability**.*Reduce amisulpride dose to 400mg daily and monitor symptoms*- Reducing the dose by half in a patient stable for 3 years carries a high risk of **psychotic relapse** or clinical instability.- Even at lower doses, **amisulpride** frequently maintains prolactin levels above the normal range due to its high affinity for **tuberoinfundibular** D2 receptors.*Continue current treatment and provide reassurance as hyperprolactinaemia is benign*- Chronic **hyperprolactinaemia** is not benign; it leads to **hypogonadism**, which increases the long-term risk of **osteoporosis** and cardiovascular disease.- Symptomatic presentation with **galactorrhoea** and **amenorrhoea** requires active management to prevent physical health complications and patient distress.
Question 55: A 29-year-old man presents with a 2-month history of believing he is Jesus Christ and that he must save humanity. He has grandiose delusions, pressured speech, reduced sleep (3 hours nightly), and has spent his entire savings. He has no past psychiatric history or substance use. Which additional feature would most strongly suggest a diagnosis of bipolar affective disorder type I rather than schizophrenia?
- A. Presence of grandiose delusions with religious content
- B. Clear episodic pattern with complete return to baseline functioning between episodes (Correct Answer)
- C. Reduced need for sleep without fatigue
- D. Family history of psychotic illness
- E. Absence of auditory hallucinations
Explanation: ***Clear episodic pattern with complete return to baseline functioning between episodes*** - **Bipolar Affective Disorder Type I** is fundamentally defined by its **episodic nature**, where patients typically achieve a **full recovery** and return to their prior level of social and occupational functioning between episodes. - In contrast, **Schizophrenia** often follows a **chronic, deteriorating course** with persistent negative symptoms or functional decline, even when active psychosis is absent. *Presence of grandiose delusions with religious content* - While common in **Mania**, religious and **grandiose delusions** are non-specific and are frequently observed in **Schizophrenia** during acute exacerbations. - The content of the delusion itself does not provide a definitive diagnostic distinction between these two **psychotic disorders**. *Reduced need for sleep without fatigue* - A **decreased need for sleep** is a hallmark symptom of a **manic episode**; however, disorganized behavior and agitation in **Schizophrenia** can also lead to significant sleep disruption. - While this feature highly supports a manic state, it does not confirm the **long-term prognosis** or episodic pattern required to differentiate it from other psychotic illnesses. *Family history of psychotic illness* - A positive **family history** for psychosis is a shared risk factor for both **Schizophrenia** and **Bipolar Disorder**, as they share significant **genetic overlap**. - This finding lacks the specificity needed to distinguish between the two diagnoses in a clinical setting. *Absence of auditory hallucinations* - The presence or absence of **hallucinations** does not differentiate the two; **Bipolar I** often presents with **psychotic features** (both hallucinations and delusions) during severe mania. - Schizophrenia can also present with delusions only (without active hallucinations) during certain phases of the illness.
Question 56: A 44-year-old woman with chronic paranoid schizophrenia on clozapine 600mg daily attends for routine blood monitoring. She is clinically well with no new symptoms. Her blood results show: WBC 2.8 × 10⁹/L, neutrophils 1.2 × 10⁹/L, platelets 245 × 10⁹/L, haemoglobin 128 g/L. What is the most appropriate immediate action?
- A. Continue clozapine and repeat blood test in 1 week as per normal monitoring
- B. Stop clozapine immediately, admit urgently, and refer to haematology (Correct Answer)
- C. Reduce clozapine dose to 400mg daily and repeat bloods in 3 days
- D. Continue clozapine but increase monitoring to twice weekly
- E. Stop clozapine immediately and start olanzapine 20mg daily
Explanation: ***Stop clozapine immediately, admit urgently, and refer to haematology*** - This patient's blood results show **neutropenia** (neutrophils 1.2 × 10⁹/L) and **leukopenia** (WBC 2.8 × 10⁹/L), both falling below the critical thresholds (neutrophils <1.5 × 10⁹/L or WBC <3.0 × 10⁹/L) that mandate immediate action in clozapine monitoring protocols. - **Immediate cessation** of clozapine is crucial to prevent progression to **agranulocytosis**, a life-threatening condition, and urgent hospital admission with hematology referral is necessary for specialized management and protective isolation. *Continue clozapine and repeat blood test in 1 week as per normal monitoring* - Continuing clozapine is **contraindicated** given the significant drop in neutrophil and white blood cell counts, which places the patient at a high risk of severe infection. - Normal weekly monitoring is only appropriate when blood counts remain within the **'Green' safety range**, which is not the case here. *Reduce clozapine dose to 400mg daily and repeat bloods in 3 days* - Dose reduction is an **insufficient intervention** for these critical blood results; clozapine must be stopped entirely to prevent further bone marrow suppression. - Delaying complete cessation and merely repeating bloods in 3 days significantly increases the risk of the patient developing **severe agranulocytosis**. *Continue clozapine but increase monitoring to twice weekly* - Increased monitoring, such as twice weekly, is typically reserved for less severe deviations (e.g., **'Amber' results** where neutrophils are 1.5-2.0 × 10⁹/L), not for the **'Red' category** values seen here. - Once blood counts fall into the 'Red' range, the drug must be **stopped immediately**, not merely monitored more frequently. *Stop clozapine immediately and start olanzapine 20mg daily* - While stopping clozapine is the correct immediate action, the priority after cessation is **medical stabilization** and assessment by hematology, not the immediate initiation of another antipsychotic. - Switching to olanzapine, even at a high dose, before the patient's hematological status is stable and evaluated could delay crucial medical care and management of potential complications.
Question 57: A 38-year-old man with bipolar affective disorder type I has been stable on lithium for 6 years. He presents to A&E with a 48-hour history of vomiting and diarrhoea following gastroenteritis. He appears clinically dehydrated. His lithium level taken 6 hours ago is 1.3 mmol/L. What is the most appropriate immediate management?
- A. Continue lithium at current dose and start oral rehydration therapy
- B. Temporarily stop lithium, admit for IV fluids and monitor lithium levels (Correct Answer)
- C. Reduce lithium dose by 50% and encourage oral fluids
- D. Continue lithium and start haemodialysis immediately
- E. Switch from lithium to sodium valproate and discharge home
Explanation: ***Temporarily stop lithium, admit for IV fluids and monitor lithium levels***- The patient exhibits features of **lithium toxicity** (1.3 mmol/L, which is above the therapeutic range of 0.4-1.0 mmol/L) exacerbated by **dehydration** from gastroenteritis, which reduces renal clearance and increases lithium retention.- Immediate **admission for IV fluid resuscitation** is crucial to restore renal function, promote **lithium excretion**, and prevent further neurotoxicity.*Continue lithium at current dose and start oral rehydration therapy*- Continuing the dose in a patient with a toxic level and active vomiting/diarrhoea will rapidly lead to **severe neurotoxicity** or renal failure.- **Oral rehydration** is often insufficient for rapid correction of electrolyte imbalances and volume depletion in the presence of ongoing gastrointestinal losses.*Reduce lithium dose by 50% and encourage oral fluids*- A simple dose reduction does not address the current **hyperlithemia** and the underlying physiological cause (dehydration).- Management requires a complete pause until levels return to the **therapeutic range** (typically 0.4–1.0 mmol/L) and renal function is stabilized.*Continue lithium and start haemodialysis immediately*- **Haemodialysis** is usually reserved for severe toxicity (levels >2.0 mmol/L with symptoms or >3.5 mmol/L if asymptomatic) or **renal failure**.- Continuing lithium while performing dialysis is counterproductive and clinically inappropriate.*Switch from lithium to sodium valproate and discharge home*- Switching medications during an acute **medical emergency** (lithium toxicity/dehydration) is unsafe and does not address the immediate risk of lithium-induced injury.- Discharging the patient is contraindicated as they require **inpatient monitoring** for hemodynamic stability and serial lithium level checks.
Question 58: A 26-year-old woman with a first episode of psychosis has been treated with aripiprazole 15mg daily for 8 weeks. Her positive symptoms have completely resolved. She asks about duration of treatment. According to current NICE guidelines, what is the minimum recommended duration of antipsychotic treatment following complete remission of a first episode of psychosis?
- A. 6 months
- B. 1 year
- C. 2 years (Correct Answer)
- D. 5 years
- E. Lifelong treatment
Explanation: ***2 years*** - According to **NICE guidelines (CG178)**, individuals who achieve complete remission after a **first episode of psychosis** should continue antipsychotic medication for at least **1 to 2 years**. - This duration is recommended to significantly reduce the high risk of **relapse** observed in the early years following the initial episode. *6 months* - This duration is insufficient for a first episode of psychosis; it is more typically associated with the minimum treatment duration for a **single episode of depression** after remission. - Discontinuing antipsychotics at 6 months carries a significantly higher risk of **early clinical relapse**. *1 year* - While some guidelines suggest a minimum of one year, **NICE clinical standards** generally favor a **1–2 year** period to ensure stability before considering tapering. - Choosing only 1 year without acknowledging the 2-year standard may lead to **premature discontinuation** in high-risk patients. *5 years* - A 5-year treatment plan is generally reserved for patients who have experienced **multiple relapses** or have a history of **serious harm** during episodes. - For a first episode with complete remission, this duration would cause unnecessary exposure to **long-term side effects** such as metabolic syndrome. *Lifelong treatment* - **Lifelong maintenance** therapy is typically only considered for patients with chronic **Schizophrenia** involving frequent, severe relapses or treatment-resistant symptoms. - For a first episode, the goal is eventually to attempt a **gradual dose reduction** and discontinuation after the stable 2-year period has passed.
Question 59: A 41-year-old man with a 15-year history of bipolar affective disorder presents with tremor, confusion, and ataxia. He takes lithium carbonate 800mg twice daily. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, urea 9.8 mmol/L, creatinine 145 μmol/L, lithium level 2.1 mmol/L. Which medication started in the past week is most likely responsible?
- A. Paracetamol for headache
- B. Ramipril for hypertension (Correct Answer)
- C. Ranitidine for dyspepsia
- D. Salbutamol inhaler for asthma
- E. Loratadine for hay fever
Explanation: ***Ramipril for hypertension***- **ACE inhibitors** like **ramipril** can significantly increase serum **lithium levels** by reducing its renal clearance.- This interaction often leads to **lithium toxicity**, consistent with the patient's symptoms of **tremor, confusion, ataxia**, and a high **lithium level of 2.1 mmol/L**. *Paracetamol for headache*- **Paracetamol** (acetaminophen) is generally considered safe with lithium and does not have a significant interaction that would cause a rise in **lithium levels**.- It does not affect **renal lithium excretion** pathways. *Ranitidine for dyspepsia*- **Ranitidine**, an H2-receptor antagonist, does not have a known significant drug interaction with lithium.- It does not impair **lithium metabolism** or **excretion**, and thus would not cause toxicity. *Salbutamol inhaler for asthma*- **Salbutamol**, a beta-2 adrenergic agonist, does not significantly interact with lithium.- There is no established mechanism by which salbutamol would increase **lithium concentrations** to toxic levels. *Loratadine for hay fever*- **Loratadine**, a non-sedating antihistamine, does not have any significant drug interactions with lithium.- It does not alter **lithium pharmacokinetics** or its elimination, making it an unlikely cause of toxicity.
Question 60: A 32-year-old woman with schizophrenia has been stable on paliperidone palmitate depot injection (150mg monthly) for 18 months. She now wishes to conceive. Her last depot injection was 2 weeks ago. What is the most appropriate management plan?
- A. Continue paliperidone depot throughout pregnancy as it is safe in all trimesters
- B. Switch immediately to oral risperidone and monitor closely during pregnancy (Correct Answer)
- C. Stop all antipsychotic medication immediately and monitor for relapse
- D. Wait 6 months after last depot injection before attempting conception
- E. Switch to clozapine as it has the best safety profile in pregnancy
Explanation: ***Switch immediately to oral risperidone and monitor closely during pregnancy*** - Switching from a **long-acting injectable (LAI)** to an **oral antipsychotic** is preferred during pregnancy planning to allow for rapid dose adjustments if side effects or complications arise. - **Risperidone** is the active metabolite (parent compound) of paliperidone, making it a logical and safer oral alternative with more documented data in pregnancy. *Continue paliperidone depot throughout pregnancy as it is safe in all trimesters* - **Depot injections** lack flexibility; if a fetus develops a complication or the mother experiences toxicity, the medication cannot be quickly washed out of the system. - While not strictly contraindicated, the **prolonged half-life** of paliperidone palmitate makes it less ideal than oral formulations for managing pregnancy transitions. *Stop all antipsychotic medication immediately and monitor for relapse* - Discontinuing treatment in a patient stable for 18 months with **schizophrenia** carries a high risk of **psychotic relapse**, which can be dangerous for both the mother and the fetus. - Expert consensus recommends maintaining stability with the **lowest effective dose** of an oral antipsychotic rather than complete cessation. *Wait 6 months after last depot injection before attempting conception* - While the depot does remain in the system for several months, delaying conception for **6 months** is often clinically unnecessary and can be distressing for the patient. - Management focuses on transitioning to **oral therapy** immediately to establish a stable dose before the patient successfully conceives. *Switch to clozapine as it has the best safety profile in pregnancy* - **Clozapine** is not first-line due to risks of **agranulocytosis**, metabolic disturbances, and the requirement for frequent **blood monitoring**, which complicates pregnancy. - It is generally reserved for **treatment-resistant schizophrenia**, and switching a stable patient to it solely for pregnancy is not recommended.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free